← All trials
NCT05974046
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2023
- Primary completion
- Jul 21, 2023
- Completion date
- Jul 21, 2023
- First posted
- Aug 3, 2023
- Last posted
- Aug 14, 2023
- Enrollment
- 7
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Indivior Inc.Lead sponsor
- Indivior Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.